Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half ...

Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults with type 2 diabetes and early-stage symptomatic PAD1 ...

Novo Nordisk (NVO) announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with type 2 diabetes and a vascular disorder known as peripheral artery ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

It's still a highly attractive market Novo Nordisk is a leader in diabetes and weight-loss medications, most prominent are their Glucagon-like-Peptide (GLP-1) drugs Wegovy and Ozempic, which are ...

March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...

Bank of America analysts on Friday said Novo Nordisk (NOVOb.CO), opens new tab may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could prompt the ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

Bloomberg has reached out to Novo Nordisk for comment on its share performance. Emily Field, an analyst at Barclays Plc, cut her estimates for US Wegovy and Ozempic sales in a note on Monday.

Eli Lilly’s weight-loss drugs, Zepbound and Mounjaro, directly rival Novo Nordisk’s Wegovy and Ozempic, intensifying the competitive landscape. Year-to-date, Novo’s shares have dropped 25% ...

The popularity of Novo Nordisk's Ozempic and Wegovy has attracted competitors and created supply constraints. Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III ...